Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) occurring in HIV-infected individuals, accounting for greater than 40% of the diagnoses (1, 2) . In the era of combination antiretroviral therapy (ART), survival of patients diagnosed with HIV-related lymphoma has significantly improved through enhanced immunity, functional status and thus tolerability to standard chemotherapy (2, 3) . However, compared to those without HIV infection, HIV-infected DLBCL patients continue to experience inferior outcomes (1) . Clinically, HIV-related DLBCL frequently presents at advanced stage, with extranodal involvement, and positive for tumor Epstein-Barr virus (EBV) infection(4). These differences suggest that lymphomas arising in the setting of HIV infection may be biologically different from that in the general population.
There are limited comparative data on molecular characteristics of DLBCL by HIV status to inform patient management and development of novel therapeutics, especially for aggressive HIV-related lymphomas. Several classes of molecular markers have been implicated in DLBCL progression in the general population. For example, the expression of cell cycle promoters, such as the cyclin family proteins, p27 and SKP2, has been linked to disease progression in DLBCL (5) (6) (7) (8) . In addition, B cell activation/proliferation markers and apoptosis regulators have also been associated with disease outcomes. Expression of anti-apoptotic proteins such as BCL2 has been linked to treatment resistance in DLBCL (9) (10) (11) . However, the roles of these markers in Our objective was to determine whether molecular pathogenic mechanisms for DLBCL are distinct for HIV-infected and HIV-uninfected patients diagnosed and managed in the ART era.
Tumor markers compared by HIV status included selected cell cycle regulators, B-cell activation markers, apoptosis regulators, and other markers that were previously identified as prognostic for DLBCL in the general population.
Materials and Methods

Study Design, Population and Setting
We included incident HIV-infected DLBCL patients and matched HIV-uninfected DLBCL Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR-14-2083 subjects 1:1 by age groups (i.e., <30, 30-50 and >50 years), gender and race (white vs. nonwhite). The KP institutional review boards approved this study and provided waivers of informed consent.
Pathology Review and Tissue Microarray Construction
The study pathologists (JS and HZ) reviewed hematoxylin and eosin stained (H&E) slides to confirm the DLBCL diagnosis and identify representative tumor blocks for tissue microarray (TMA) construction. Whenever possible, three 1.2-mm cores from different areas of the donor block were obtained from each patient and inserted in a grid pattern into a recipient paraffin block using a tissue arrayer (Beecher Instruments, Silver Spring, MD).
Immunohistochemistry Staining
Immunohistochemistry staining was performed on TMA cores to analyze the expression of selected B-cell oncogenic markers in the following categories: (1) cell cycle promoters, including cyclin E, cMYC, p27, SKP2; (2) B-cell activators/differentiation, including BCL6, FOXP1, PKC-beta 2, CD21 and CD10; (3) apoptotic regulators, including BCL2, p53, survivin, BAX, GAL3, and BLIMP1; and (4) others, including MUM1, Ki-67, CD44, CD30, CD43, LMO2, MMP9 and IgM. All markers were selected on the basis of previously reported prognostic significance in DLBCL in the general population. Co-expressions of cMYC and BCL2, and of cMYC, BCL2 and BCL6 were also evaluated (14, 15) . Expression of CD10, MUM1 and BCL6 were used to determine the germinal center (GC) phenotype using the Hans' algorithm (16) . Sections from paraffin-embedded blocks were cut at 4 μm and paraffin removed with xylene and rehydrated through graded ethanols. Heat-induced antigen retrieval and Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- proteolytic induced epitope retrieval were used. Following this pretreatment the slides were incubated with primary antibodies for the markers of interest. The detailed antibody information, incubation method and signal detection for each marker were described elsewhere (17) . All staining was performed manually. Normal tonsillar lymphoid tissue was included as a positive control. Negative controls for each case consisted of substituting the primary antibody with isotype specific non-cross reacting antibody matching the primary antibody.
The percent of DLBCL cells with visible marker staining was scored on a scale from 0-4 (0: 0-9%, 1: 10-24%, 2: 25-49%, 3: 50-74% and 4: ≥75%). Scoring was performed manually by one study pathologist and confirmed by another study pathologist for all markers except for Ki-67, which was scored on a computerized automated image analysis platform (Definiens TissueStudio). Cases with discrepant scores (about 10%) were resolved by re-review with double headed microscope. Tumor EBV infection status was not included in the current analyses since we evaluated this marker in our previous study (17) 
Ascertainment of Patient Survival
Two-year mortality was chosen as the outcome since most deaths in HIV-infected patients (85% in our study) occurred within 2 years after DLBCL diagnosis. Mortality ascertainment was complete for all subjects, even in the event of termination of KP membership, through record linkage with KP's membership and utilization files, California's state death file, and social security death records. As such, there was no loss-to-follow up for the mortality outcomes.
Covariates
The standard International Prognostic Index (IPI) was calculated based on age, clinical stage, extranodal involvement, serum lactose dehydrogenase (LDH), and Eastern Cooperative Oncology Group (ECOG) performance status (18, 19) . Age at DLBCL diagnosis, stage at diagnosis and extranodal involvement were collected from KP's cancer registries. Serum LDH level at DLBCL diagnosis was obtained from KP's laboratory databases. Health service utilization records, including home health visits, hospitalization and rehabilitation, and comorbidity status were used to estimate performance status (20) . Among HIV-infected DLBCL patients, we also collected HIV disease factors from KPs HIV registries, including prior AIDS diagnosis, use of ART, and duration of known HIV infection. CD4 cell counts at DLBCL diagnosis and lowest (nadir) recorded at KP were obtained from KP's laboratory databases.
Information on the receipt of chemotherapy was collected from KP's cancer registries. In addition, information on disease progression and relapse was collected via manual chart review for HIV-infected patients for analysis to confirm the prognostic role of any tumor markers found to predict increased mortality in HIV-infected DLBCL patients.
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Statistical Analysis
The demographic and DLBCL characteristics were compared between patients who were HIVinfected versus -uninfected. The mean and standard deviation of the expression score (staining score) for each tumor marker was calculated by HIV status. Tumor marker expression was also considered as "positive" or "negative" based on previously published cut-off values for each marker, and compared using Fisher's exact test. Due to the small sample size in the analytical subcohort, p-value <0.10 was used as the cut-off for statistical significance in this study.
Bonferroni's method was used to adjust for multiple comparisons(21).
For markers that were differentially expressed by HIV status, their expression levels within the GC phenotype, the non-GC phenotype, and within the centroblastic variant (the most common DLBCL variant) were also examined. Associations between clinical stage, extranodal involvement and expression of these markers were further examined in HIV-infected patients.
Since HIV-related lymphomagenesis is related to immunosuppression, we hypothesized that differential expression of oncogenic markers by HIV status may be driven by differences in immune function. To test this hypothesis, the associations between prior AIDS diagnosis, prior ART use, CD4 cell counts, both at DLBCL diagnosis and the lowest recorded at KP, and tumor marker positivity were examined using t-test in HIV-infected patients.
To explore if the different molecular characteristics of DLBCL may explain the more aggressive clinical course in HIV-related DLBC, the prognostic significance of markers that were differentially expressed by HIV status was examined. Kaplan-Meier survival curves for each of these markers were generated. The association between tumor marker positivity and two-year overall mortality was examined using bivariate and multivariable logistic regression, adjusting for IPI, GC phenotype, DLBCL variants (centroblastic, immunoblastic and plasmablastic) and chemotherapy treatment. These analyses were performed separately for HIV-infected anduninfected patients. Missing data were handled using the multiple imputation method proposed by Rubin in these analyses (22) . For markers found to predict increased mortality in HIV-infected patients, the analyses was also repeated for progression-free survival. Disease progression was defined as relapse after complete remission or progression after partial remission or nonresponse.
All analyses were performed with SAS Version 9.2; Cary, North Carolina, USA.
Results
The characteristics of the 80 HIV-infected and the 80 matched HIV-uninfected DLBCL patients are presented in Table 1 . The mean age at DLBCL diagnosis was similar by HIV status (50 years) due to matching. The majority of the patients were male (~90%) and of non-Hispanic white (~60%). HIV-infected patients with DLBCL, compared with HIV-uninfected patients, were more likely to be diagnosed at advanced cancer stage (48% and 29%; p=0.01), with extranodal involvement (43% vs. 11%, p<0.01) and have germinal center phenotype (39% vs. 26%; p=0.01). HIV-infected patients had a mean CD4 cell count of 206 cells/mm 3 at DLBCL diagnosis, and a mean 5-years duration of known HIV infection prior to DLBCL diagnosis.
Among the HIV-infected DLBCL patients, a total of 37 deaths (46%) occurred during the twoyear follow-up ( Table 1) . By contrast, only 13 (16%) deaths occurred in the two-year period among the 80 matched HIV-uninfected DLBCL patients.
Research.
on April 
HIV infection status and tumor marker expression
The expression of the following tumor markers were found to be substantially different in HIVinfected patients: an elevated expression was observed for cMYC, BCL6, PKC-beta2, MUM1, CD44, CD30, MMP9 and IgM; while a reduced expression was observed for p27, FOXP1, and GAL3 ( Table 2) . After accounting for multiple comparisons, the differences by patient HIV status remained statistically significant for cMYC, p27, BCL6, PKC-beta2, MUM1 and CD44.
Of these six markers, the greatest difference in expression level was seen for PKC-beta2: mean expression level was 2.7 (standard deviation: 1.7) in HIV-related and 0.5 (0.8) for HIV-unrelated DLBCL.
DLBCLs in HIV-infected patients also more frequently presented with co-expression of cMYC and BCL2 (25% vs. 14%, Table 2 , bottom), and of cMYC, BCL2 and BCL6 (8% vs. 1%).
Tumor marker expression by cell of origin phenotype and in centroblastic subtype Statistically significant differences in expression of cMYC, p27, BCL6, PKC-beta2, MUM1 and CD44 by HIV status continued to be observed within subgroups defined by cell-of-origin (data not shown). Similar results were found when we restricted the analyses to only the centroblastic variant (data not shown).
Associations between tumor marker expression and DLBCL clinical characteristics
No clear association was found between DLBCL clinical stage and expression of cMYC, p27, BCL6, PKC-beta2, MUM1 and CD44 within HIV-infected patients ( Table 3) . p27 and BCL6 expression were found to be associated with increased and decreased extranodal involvement in HIV-infected patients, respectively. However, the directions of these associations do not explain the more frequent extranodal involvement in HIV-related DLBCL compared to HIV-unrelated DLBCL.
Tumor marker expression by immune status
We did not find an association between prior AIDS diagnosis, prior ART use or CD4 cell count and expression of cMYC, p27, BCL6, PKC-beta2 and CD44 (data not shown for prior AIDS or ART use) in patients with HIV-related DLBCL. MUM1 expression, however, was found to be positively associated with prior AIDS diagnosis: 70% in those with prior AIDS expressed MUM1, compared to 47% in those without prior AIDS (p-value=0.04). This is consistent with the finding that a significantly lower CD4 cell count, both at DLBCL diagnosis and as the lowest recorded at KP, was observed in those positive for MUM1 expression compared to those without MUM1 expression ( Table 4) .
Tumor marker expression and two-year mortality by HIV infection status 
cMYC is a transcription factor that plays an important role in regulating proliferation, cell growth, apoptosis, and metabolism (23) . Persistent expression of cMYC leads to the dysregulation of many genes, including the cyclin family proteins. Dysregulation of cMYC has also been linked to treatment resistance in several cancer models (24, 25) . Consistent with the notion that MYC gene alterations in DLBCL are often associated with BCL6 translocation (14), we also observed elevated expression of BCL6. BCL6 expression is usually associated with the GC phenotype, a subtype of DLBCL with favorable prognosis under standard chemotherapy, although BCL6 can also be found in activated B-cell DLBCL. In our study, even after restricting to the GC subtype, end, we explored the hypothesis that expression of these oncogenic markers was driven by mechanisms related to immunosuppression in the HIV-infected cohort. We did not find associations between the expression of most of these markers and level of CD4 cell count, except for MUM1 expression, which was associated with a reduced CD4 cell count. Consistent with this finding, a lower nadir CD4 cell count (but not CD4 cell count at DLBCL diagnosis) was also found among those with non-GC subtype compared to the those with GC subtype [mean (SD) was 63 (69) cells/mm3 versus 90 (66) cells/mm3, p-value=0.10]. However, it should be noted that most of our HIV-infected patients (75 out of 80) experienced a nadir CD4 cell count of less than 200 cells/mm 3 . Given the limited range of nadir CD4 cell count in our cohort, the lack of associations between CD4 cell count and most of these markers do not entirely exclude the possibility that immunosuppression in HIV-infected patients selectively promote these molecular pathogenic mechanisms compared to HIV-uninfected patients.
Another potential mechanism that may drive the differential marker expression by HIV status is EBV-induced pathogenesis. We have previously reported on the association between tumor EBV status and oncogenic tumor marker expression in the same HIV-infected DLBCL patients (17) .
EBV positivity was found in 30% of our HIV-infected and 10% of the matched HIV-uninfected DLBCL patients, respectively. However, expression of most of the six markers, except BCL6, was not associated with tumor EBV status in HIV-related DLBCL. Moreover, tumor EBV infection was inversely associated with BCL6 expression, which does not explain the elevated expression of BCL6 in HIV-related DLBCL. It should be noted that due to the small sample size of these sub-analyses, these comparisons should be considered exploratory.
Research. Interestingly, several markers, such as p27 and CD44, appear to have opposite prognostic implications for HIV-infected and HIV-uninfected patients. For example, while CD44 expression was associated with increased mortality in HIV-uninfected patients (not statistical significant), the relative risk was less than unity for HIV-infected patients. The prognostic significance of p27 has been controversial even within DLBCL in the general population (7, 31, 32) . In our analyses, p27 expression was associated with a reduced mortality in HIV-uninfected patients, but this was not the case in HIV-infected patients. However, given the overlapping confidence intervals of these estimates in HIV-infected vs. -uninfected patients (that are likely a result of the small sample sizes), additional studies will be needed to clarify if these molecules play a different role in disease progression in HIV-related DLBCL from DLBCL in the general population. any one of the three translocations. However, this study mainly included patients diagnosed in the pre-ART era where EBV infection was seen in most HIV-infected patients (i.e., >60% vs. 30% in our study, which is based on patients in the ART era). Thus their results may not be generalizable to patients diagnosed in the ART era.
A potential limitation of this study was the limited sample size for certain subgroup comparisons and prognostic analysis for the matched HIV-uninfected DLBCL patients for whom there were fewer death events. This may explain the lack of statistical significance of cMYC and PKC-beta2 in HIV-uninfected DLBCL patients despite potentially meaningful magnitudes of associations.
Also, we choose a cut-off value for defining cMYC-positivity (i.e., ≥10% expression) based on Copie-Bergman et al.(31), while a higher cut-off has been recommended by others. To this end, in our sensitivity analysis using a higher cut-off value, i.e., ≥50% to define cMYC positivity, 
HIV-related DLBCL patients continues to have elevated expression (26% cMYC-positive compared to 1% in HIV-unrelated DLBCL patients, p<0.01).
In conclusion, our study is based on a well-defined cohort of HIV-infected DLBCL patients from the ART era that is among the largest reported in the literature for the tumor marker analysis. In addition, the comparisons conducted with an internally matched HIV-uninfected DLBCL cohort from the same managed care population minimizes confounding in survival outcomes due to differential access to care or population characteristics. Our data suggest that DLBCL pathogenesis in the context of HIV infection more frequently involves over expression of several transcription regulators, including cMYC, BCL6 and MUM1, as well as cell signaling pathways related to PKC-beta2 and CD44. In particular, cMYC expression is associated with increased mortality in both HIV-infected and -uninfected DLBCL patients, independent of established prognostic factors. Given that cMYC is expressed in two-thirds of the HIV-related DLBCL tumors compared to one-third of HIV-unrelated DLBCL, cMYC-mediated pathogenic mechanisms may in part explain the poorer clinical outcomes in HIV-infected DLBCL patients.
These results suggest that cMYC may serve as a novel therapeutic target for HIV-related DLBCL. Future studies should examine if the elevated cMYC expression in HIV-related DLBCL is associated with gene rearrangement and the double-hit or the triple hit (with BCL2 and/or BCL6) lymphomas, which may further inform patient risk stratification and treatment.
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